News

Epileptic activity appear to be more frequent in patients with Alzheimer’s disease than in healthy individuals and may be linked to disease progression, according to a recent study. These findings, previously seen in animals, suggest that increased neuronal excitability, a feature of epilepsy, may also contribute to the onset and progression of…

Medical marijuana’s potential as an effective treatment for the progression of Alzheimer’s disease is high on the list of discussion topics as more than 300 medical practitioners, attorneys and industry experts gather for the second annual South Florida Medical Cannabis Symposium to be held at the Westin Fort…

The non-profit UsAgainstAlzheimers organization has started a program that has a key goal of addressing African-American and Latino underrepresentation in neurological research. Recognizing that Alzheimers disproportionately affects people of color, another goal of the program will be to build a national network of doctors, researchers, patients, caregivers and others involved…

Trials of deep brain stimulation for Alzheimer’s disease bring with them unique ethical challenges that need to be addressed because these studies are progressing, researchers argue in a recent review article. The trio behind the review — researchers from the University of Pennsylvania — not only raised points for concern, but also provided potential…

High levels of air pollution particles may increase the risk of dementia and Alzheimer’s disease in older women, according to results of a new study. These particles, found in emissions from power plants and cars, increase the risk of dementia, including Alzheimer’s, by as much as 92%, especially in women…

Low glucose levels in the brain are known to lead memory problems and cognitive decline, and new research suggests they do so by triggering a series of molecular reactions that ultimately kill neurons. These findings provide fresh insight into changes that set the stage for Alzheimer’s disease. The research also identified a protein that appears…

Dan Gasby, a television producer, author, and Alzheimer’s disease advocate, is teaming up with the nonprofit American Brain Foundation (ABF) to support and advance research into brain and nervous system disorders, especially for African-Americans. He’ll undoubtedly be a strong voice on the ABF’s board of directors, to which he was recently appointed.

Researchers believe that processes that can be used to control immune reactions toward a virus may also be used to prevent neurodegeneration in conditions such as Alzheimer’s disease. To achieve this, researchers blocked the protein PLSCR1 in the brain — a move that prevented immune cells called microglia from attacking…

Neuronascent has been issued a U.S. patent for methods of stimulating neurogenesis and/or inhibiting neuronal degeneration that have potential therapeutic applications in Alzheimer’s disease, Parkinson’s disease, post-traumatic stress disorder, depression, and other psychiatric disorders. The biopharma Neuronascent discovers and develops novel therapeutics aimed at halting or reversing neurological disorders. The…

Researchers at Georgetown University Medical Center (GUMC) are recruiting participants for a clinical trial to evaluate the cancer drug Tasigna (nilotinib) in people with mild to moderate Alzheimer’s disease (AD). The randomized, double-blind, placebo-controlled Phase 2 clinical trial (NCT02947893) will evaluate how low doses of Tasigna impact safety, biomarkers, and…